Glycemic optimization
Glycemic optimization has been studied in 1 paper since 2026: 1 trial in people; 1 in the past year. The newest paper, Mar 6, 2026: “Impact of glycemic optimization on myocardial steatosis and cardiac remodeling in patients with newly diagnosed type 2 diabetes: a longitudinal study”.
1 paper studies it4 findingsUpdated
See all 1 papers on glycemic optimization
At a glance
The findings reach people, from one lab or study. 1 lab in 1 country.
“Participants (mean age 54.8 ± 9 years, 72.3% male) achieved significant reductions in HbA1c levels, body mass index (BMI) and waist circumference (WC).”
None of its findings points the other way.
- 1 lab in 1 country
- Funders: Agència de Gestió d'Ajuts Universitaris i de Recerca and others
- Human trial1
Studies in people
1 study gave glycemic optimization to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
down: Decreases HbA1c no change: Has no effect on myocardial triglyceride contentp = 0.23 up: Increases left ventricular ejection fraction59.0% [54.8-61.5] vs. 63.1% [56.9-66.3], p = 0.01 | Trial12 months | 20 peopleBothmean age 54.8 ± 9 yearsMidlife adults; newly diagnosed type 2 diabetes | Cardiovascular diabetology, Mar 6, 2026 |
What did studies of glycemic optimization find?
4Studies of glycemic optimization measured 4 outcomes, among them Left ventricular end-systolic volume, left ventricular ejection fraction and myocardial triglyceride content.
Left ventricular end-systolic volume
downin humans1
1 study
Left ventricular end-systolic volume
downin humans1
Glycemic optimization decreases Left ventricular end-systolic volume in humans (newly diagnosed type 2 diabetes) (29.9 mL/m2 [26.4-35.1] vs. 27.3 mL/m2 [22.5-31.7]; p = 0.007).
“decreases in ventricular volumes: (LV) end-systolic volume (29.9 mL/m2 [26.4-35.1] vs. 27.3 mL/m2 [22.5-31.7]; p = 0.007)”
Human trialnewly diagnosed type 2 diabetes12 monthsn = 20
Cardiovascular diabetology
Left ventricular ejection fraction
upin humans1
1 study
Left ventricular ejection fraction
upin humans1
Glycemic optimization increases left ventricular ejection fraction in humans (newly diagnosed type 2 diabetes) (59.0% [54.8-61.5] vs. 63.1% [56.9-66.3], p = 0.01).
“CMR evaluation revealed increases in left ventricle (LV) ejection fraction (59.0% [54.8-61.5] vs. 63.1% [56.9-66.3], p = 0.01)”
Human trialnewly diagnosed type 2 diabetes12 monthsn = 20
Cardiovascular diabetology
Myocardial triglyceride content
no changein humans1
1 study
Myocardial triglyceride content
no changein humans1
Glycemic optimization showed no clear effect on myocardial triglyceride content in humans (newly diagnosed type 2 diabetes) (p = 0.23).
“No significant changes in MTGC were found at follow-up (p = 0.23).”
Human trialnewly diagnosed type 2 diabetes12 monthsn = 20
Cardiovascular diabetology
HbA1c
downin humans1
1 study
HbA1c
downin humans1
Glycemic optimization decreases HbA1c in humans (newly diagnosed type 2 diabetes).
“Participants (mean age 54.8 ± 9 years, 72.3% male) achieved significant reductions in HbA1c levels, body mass index (BMI) and waist circumference (WC).”
Human trialnewly diagnosed type 2 diabetes12 monthsn = 20
Cardiovascular diabetology